Vimarsana
Biggest News Aggregation in the World

Page 5 - Nat Microbiol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nat Microbiol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nat Microbiol Today - Breaking & Trending Today

Frontiers | Reversible Bronchiectasis in COVID-19 Survivors With Acute Respiratory Distress Syndrome: Pseudobronchiectasis - Vimarsana News

Frontiers | Reversible Bronchiectasis in COVID-19 Survivors With Acute Respiratory Distress Syndrome: Pseudobronchiectasis

To retrospectively analyze whether traction bronchiectasis was reversible in coronavirus disease 2019 (COVID-19) survivors with acute respiratory distress syndrome (ARDS) and whether CT findings were associated with the reversibility, 41 COVID-19 survivors with ARDS were followed up for more than four months. Demographics, clinical data, and all chest CT images were collected. The follow-up CT images were compared with the previous CT scans. Twenty-eight (68%) patients with traction bronchiectasis (Group I) and 13 (32%) patients without traction bronchiectasis (Group II) on CT images. Traction...

Antibody Protection Against Harmful Gut Fungi May Be Disrupted in Crohn's Disease - Vimarsana News

Antibody Protection Against Harmful Gut Fungi May Be Disrupted in Crohn's Disease

According to a new study, antibody protection against harmful forms of fungi in the gut may be disrupted in some patients with Crohn’s disease.

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection - Vimarsana News

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, Regeneron, ZMapp and MAb114) have been evaluated in a RCT, the Pamoja Tulinde Maisha (PALM) study. Tw...

Frontiers | Eosinophil: A Nonnegligible Predictor in COVID-19 Re-Positive Patients - Vimarsana News

Frontiers | Eosinophil: A Nonnegligible Predictor in COVID-19 Re-Positive Patients

2Department of Microbiology, Linyi Center for Disease Control and Prevention, Linyi, China 3Department of Immunology, School of Basic Medicine, Qingdao University, Qingdao, China 4Department of Infectious Disease, The Affiliated Hospital of Qingdao University, Qingdao, China 5Department of Medical Education, Qingdao Chest Hospital, Qingdao, China 6Department of Infectious Disease, Qingdao Centre for Disease Control and Prevention, Qingdao Institute of Prevention Medicine, Qingdao, China 7Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China Althou...

Counter Point: Dozens of experts challenge the Covid 19 vaccine - Vimarsana News

Counter Point: Dozens of experts challenge the Covid 19 vaccine

There are two certainties about the Covid-19 vaccines being mass-distributed around the world. The first is that governments and the vast majority of mainstream media are pushing with as much ferocity as they can muster for these experimental drugs to be injected into as many people as possible. The second is that those who are brave enough to face the scorn that comes with asking serious questions about the vaccines are absolutely necessary components of our ongoing fight to spread the truth. NOQ Report received an advanced copy of the manuscript in preprint below. It has been prepared by ne...